PROSTOX™

Are you considering radiation therapy for prostate cancer?



PROSTOX is a new genetic test that helps prostate cancer patients avoid radiation toxicity

Radiation Therapy for Prostate Cancer

Radiation therapy (RT) is used to non-invasively destroy cancer cells. Advances in technology have led to the development of Stereotactic Body Radiation Therapy (SBRT), a technique where radiation is directed to the prostate. SBRT provides a high dose of radiation over a short period of time, usually five sessions or less.

Potential Side effects from SBRT

Generally, SBRT is very effective, and most men experience mild, short-lived side effects that do not persist. However, about 15% of men experience severe side effects that can start months or even years following SBRT. These late genitourinary (GU) toxicities can include hematuria, urinary tract pain, increased frequency of urination or urinary urgency and leaking. **Fortunately, PROS**TOX **is a new DNA test which can identify men at high-risk for late GU toxicity, so options can be considered to help avoid side effects.**

What is **PROS**TOX?

PROSTOX is a non-invasive laboratory test that analyzes individual's risk of developing late GU toxicity following SBRT for prostate cancer.

The test will tell your physician if you are at low risk or high risk for late GU radiation toxicity. Knowing this risk before starting SBRT is important, so that you and your doctor can decide together what course of treatment is right for you.

How Do I Get a **PROS**TOX **Test?**

Your doctor will recommend the test for you. You will receive a collection kit with an oral swab and collection vial. Once you swab the inside of your cheek and place it in the vial, you can send it directly to the MiraDX laboratory in the supplied prepaid box. Your doctor will receive the results in about 3-5 days from the time your sample is received in the lab.

For more information, please talk to your doctor or contact us at **PROS**TOX@miradx.com or call 424-387-8100.

MiraDx is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The PROSTOX test was developed, and its performance characteristics determined by MiraDx. It has not been reviewed by the U.S. Food and Drug Administration. This test is intended for use as an aid to clinicians for patient management decisions about the risk of late grade >= 2 toxicity from radiation therapy for prostate cancer. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician and relevant guidelines on the management of prostate cancer using radiation therapy.

RESEARCH PUBLICATIONS

JAMA Oncol 2018:4:e180039.
Int J Radiat Oncol Biol Phys 2018;102:296-303.
Lancet 2019;394:385-95.
JAMA Network Open 2019;2:e188006.
Journal of Clinical Oncology 2020;38(6):163-163.
Journal Radiotherapy and Oncology 2022;167:226-232.

miraDX 11601 Wilshire Blvd. Ste 105, Los Angeles, CA 90025 | Phone: 424-387-8100 | Fax: 424-387-8101

v1.4 03.2024